X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (451) 451
index medicus (249) 249
male (183) 183
female (181) 181
oncology (165) 165
lymphoma, large-cell, anaplastic - enzymology (152) 152
anaplastic lymphoma kinase (137) 137
lymphomas (137) 137
receptor protein-tyrosine kinases (129) 129
middle aged (125) 125
adult (116) 116
animals (115) 115
cancer (108) 108
immunohistochemistry (107) 107
protein-tyrosine kinases - metabolism (103) 103
hematology (101) 101
pathology (101) 101
expression (95) 95
receptor protein-tyrosine kinases - metabolism (88) 88
aged (86) 86
lymphoma, large-cell, anaplastic - pathology (86) 86
receptor protein-tyrosine kinases - genetics (85) 85
hemic and lymphatic diseases (83) 83
non-hodgkins-lymphoma (82) 82
cell line, tumor (81) 81
alk (77) 77
protein-tyrosine kinases - genetics (77) 77
gene (70) 70
adolescent (69) 69
child (67) 67
lymphoma (64) 64
lymphoma, large b-cell, diffuse - enzymology (63) 63
apoptosis (60) 60
lymphoma, large-cell, anaplastic - genetics (60) 60
research (59) 59
genetic aspects (58) 58
receptor protein-tyrosine kinases - antagonists & inhibitors (57) 57
npm-alk (55) 55
cell biology (54) 54
kinases (54) 54
lung neoplasms - enzymology (54) 54
mutation (54) 54
prognosis (54) 54
large-cell lymphoma (53) 53
proteins (53) 53
mice (52) 52
phosphorylation (52) 52
crizotinib (51) 51
fusion (48) 48
anaplastic large cell lymphoma (47) 47
aged, 80 and over (45) 45
non-hodgkin's lymphomas (45) 45
receptor tyrosine kinase (45) 45
identification (44) 44
in situ hybridization, fluorescence (43) 43
carcinoma, non-small-cell lung - enzymology (42) 42
gene expression regulation, neoplastic (42) 42
protein kinase inhibitors - therapeutic use (42) 42
tumors (42) 42
antineoplastic agents - therapeutic use (41) 41
protein kinase inhibitors - pharmacology (40) 40
lung-cancer (39) 39
lymphoma, large b-cell, diffuse - pathology (39) 39
analysis (38) 38
health aspects (37) 37
translocation (37) 37
child, preschool (36) 36
lymphoma, large-cell, anaplastic - diagnosis (36) 36
lymphoma, large-cell, anaplastic - drug therapy (36) 36
neoplasms - enzymology (36) 36
tyrosine kinase (36) 36
activating mutations (35) 35
care and treatment (35) 35
lung neoplasms - drug therapy (35) 35
neuroblastoma (35) 35
biomarkers, tumor - metabolism (34) 34
chemotherapy (34) 34
signal transduction (34) 34
translocation, genetic (34) 34
lung neoplasms - genetics (33) 33
lung neoplasms - pathology (33) 33
protein (33) 33
treatment outcome (33) 33
antineoplastic agents - pharmacology (32) 32
carcinoma, non-small-cell lung - drug therapy (32) 32
protein-tyrosine kinases - analysis (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
biomarkers, tumor - analysis (31) 31
diagnosis (30) 30
gene expression (30) 30
lung cancer, non-small cell (30) 30
activation (29) 29
biochemistry & molecular biology (29) 29
gene rearrangement (29) 29
lung cancer (29) 29
cell lung-cancer (28) 28
kinase (28) 28
lymphoma, large b-cell, diffuse - genetics (28) 28
pyridines - therapeutic use (28) 28
article (27) 27
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 472 - 480
Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,... 
Hematology, Oncology and Palliative Medicine | LUNG-CANCER | FUSION | GENE | ONCOLOGY | ADOLESCENTS | RESISTANCE | ALK KINASE | ONCOGENIC MUTATIONS | IDENTIFICATION | ACTIVATING MUTATIONS | CHEMOTHERAPY | Pyrazoles - therapeutic use | Age Factors | Humans | Child, Preschool | Pyridines - pharmacokinetics | Infant | Male | Antineoplastic Agents - therapeutic use | Lymphoma, Large-Cell, Anaplastic - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Pyridines - adverse effects | Neoplasms - genetics | Time Factors | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Biomarkers, Tumor - antagonists & inhibitors | Pyrazoles - pharmacokinetics | Child | Lymphoma, Large-Cell, Anaplastic - genetics | Pyrazoles - adverse effects | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Neoplasms - enzymology | Treatment Outcome | Receptor Protein-Tyrosine Kinases - metabolism | Disease Progression | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Adolescent | Biomarkers, Tumor - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Mutation | Neoplasms - pathology | Consortia | Pediatrics | Lymphomas | Safety and security measures | Lung cancer, Non-small cell
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 9/2010, Volume 107, Issue 37, pp. 16228 - 16233
Journal Article
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 88, Issue 4, pp. 892 - 898
Purpose To analyze the durability and toxicity of radiotherapeutic local ablative therapy (LAT) applied to extra-central nervous system (eCNS) disease... 
Radiology | Hematology, Oncology and Palliative Medicine | SURVIVAL | GENE | ONCOLOGY | RESECTION | LIVER | PHASE I/II TRIAL | COLORECTAL-CARCINOMA METASTASES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Lymphoma, Large-Cell, Anaplastic - enzymology | Radiosurgery - adverse effects | Young Adult | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Radiosurgery - methods | Pyridines - therapeutic use | Radiotherapy Dosage | Lymphoma, Large-Cell, Anaplastic - therapy | Lung Neoplasms - enzymology | Drug Administration Schedule | Survival Rate | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Lymphoma, Large-Cell, Anaplastic - mortality | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - enzymology | Care and treatment | Cancer patients | Nuclear radiation | Analysis | Central nervous system | Development and progression | Lymphomas | Radiotherapy | Lung cancer, Non-small cell | Index Medicus | LYMPHOMAS | PATIENTS | DOSE EQUIVALENTS | LUNGS | RADIOLOGY AND NUCLEAR MEDICINE | CENTRAL NERVOUS SYSTEM | TOXICITY | RADIOTHERAPY
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 2013, Volume 13, Issue 10, pp. 685 - 700
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell... 
ANAPLASTIC LYMPHOMA KINASE | MOLECULAR CHARACTERIZATION | LUNG-CANCER | NPM-ALK | ONCOLOGY | INFLAMMATORY MYOFIBROBLASTIC TUMOR | DOWN-REGULATION | TRUNCATED FORM | FUSION GENE | LARGE-CELL LYMPHOMA | GROWTH-FACTOR | Translocation, Genetic | Pyrazoles - therapeutic use | Humans | Neoplasm Proteins - physiology | Receptor Protein-Tyrosine Kinases - biosynthesis | Receptor Protein-Tyrosine Kinases - physiology | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Lymphoma, Large-Cell, Anaplastic - enzymology | Oncogene Proteins, Fusion - physiology | Protein-Tyrosine Kinases - physiology | Drosophila Proteins - physiology | Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | Gene Expression Regulation, Developmental | Neoplasm Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - genetics | Pyridines - therapeutic use | Signal Transduction | Neoplasm Proteins - biosynthesis | Enzyme Induction | Models, Molecular | Neoplasms - enzymology | Neoplasm Proteins - chemistry | Clinical Trials as Topic | Zebrafish Proteins - physiology | Neoplasms - drug therapy | Animals | Receptor Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Protein Conformation | Caenorhabditis elegans Proteins - physiology | Mice | Mutation | Receptor Protein-Tyrosine Kinases - chemistry | Crizotinib | Care and treatment | Lymphomas | Dosage and administration | Research | Cancer | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article